Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population
- 1Gwangju Alzheimer's and Related Dementia Cohort Research Center, Chosun University, Gwangju 61452, Republic of Korea
Abstract
Background: Plasma phosphorylated tau 217 (pTau217) is a robust biomarker of Alzheimer's disease (AD) pathology. However, whether a single biomarker can adequately capture both clinical diagnosis and disease progression remains unclear. We investigated the complementary roles of plasma AD biomarkers and routinely measured metabolic markers across different stages of AD. Methods: Using the Gwangju Alzheimer's & Related Dementia (GARD) cohort, we analyzed cross-sectional and longitudinal data, including amyloid-PET, MRI, neuropsychological examinations, and APOE genotypes. Plasma pTau217, GFAP, and NfL levels were measured alongside routine biochemical markers to evaluate their associations with pathology and neurodegeneration. Results: Plasma pTau217 best identified amyloid-PET positivity (AUC > 0.91). For AD diagnosis, adding cholesterol and glucose to pTau217 improved the AUC from 0.781 to 0.873. To predict progression in amyloid-positive individuals, glucose alone outperformed pTau217 (AUC 0.840 vs. 0.747), whereas adding GFAP yielded the strongest prognostic performance (AUC 0.867). Discussion: Plasma pTau217 primarily reflects amyloid pathology, whereas metabolic markers provide complementary information related to the clinical expression and progression of the disease. Integrating biomarkers across distinct biological domains may improve risk stratification and prognostic assessment in AD.
Related
- Tau PET Braak staging across the Alzheimer Disease continuum using Flortaucipir and MK6240
- Sex-Divergent Patterns in Hippocampal and Cortical NMDA Receptor Density Across the Alzheimer's Disease Continuum.
- Acupuncture-related brain network findings across clinical stages of the Alzheimer’s disease continuum: a critical review of functional MRI evidence
- Diagnostic Utility of Multi-Domain Language Measures Across the Alzheimer Disease Continuum
- Plasma eMTBR-tau as a marker of clinical stage and progression across the Alzheimer's disease continuum
BibTeX
@misc{kang2026bloodbased,
title = {{Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population}},
author = {S. Kang and Y. Y. Choi and M. Kim and K. Y. Choi and E. H. Seo and H. Hwang and J. Y. Chung and J. Kim and H.-C. Song and H. Kim and Y. Choe and G. R. Jun and K. H. Lee},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.27.26366659},
url = {https://www.medrxiv.org/content/10.64898/2026.10.27.26366659v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population
AU - S. Kang
AU - Y. Y. Choi
AU - M. Kim
AU - K. Y. Choi
AU - E. H. Seo
AU - H. Hwang
AU - J. Y. Chung
AU - J. Kim
AU - H.-C. Song
AU - H. Kim
AU - Y. Choe
AU - G. R. Jun
AU - K. H. Lee
PY - 2026
DA - 2026/10/27
PB - medRxiv
DO - 10.64898/2026.10.27.26366659
UR - https://www.medrxiv.org/content/10.64898/2026.10.27.26366659v1
AB - Background: Plasma phosphorylated tau 217 (pTau217) is a robust biomarker of Alzheimer's disease (AD) pathology. However, whether a single biomarker can adequately capture both clinical diagnosis and disease progression remains unclear. We investigated the complementary roles of plasma AD biomarkers and routinely measured metabolic markers across different stages of AD. Methods: Using the Gwangju Alzheimer's & Related Dementia (GARD) cohort, we analyzed cross-sectional and longitudinal data, including amyloid-PET, MRI, neuropsychological examinations, and APOE genotypes. Plasma pTau217, GFAP, and NfL levels were measured alongside routine biochemical markers to evaluate their associations with pathology and neurodegeneration. Results: Plasma pTau217 best identified amyloid-PET positivity (AUC > 0.91). For AD diagnosis, adding cholesterol and glucose to pTau217 improved the AUC from 0.781 to 0.873. To predict progression in amyloid-positive individuals, glucose alone outperformed pTau217 (AUC 0.840 vs. 0.747), whereas adding GFAP yielded the strongest prognostic performance (AUC 0.867). Discussion: Plasma pTau217 primarily reflects amyloid pathology, whereas metabolic markers provide complementary information related to the clinical expression and progression of the disease. Integrating biomarkers across distinct biological domains may improve risk stratification and prognostic assessment in AD.
ER -